Personalis (NASDAQ:PSNL) Upgraded at Wall Street Zen

Personalis (NASDAQ:PSNL) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other research analysts also recently weighed in on the company. BTIG Research restated a “buy” rating and issued a $12.00 price target on shares of Personalis in a research note on Friday, January 9th. Guggenheim increased their price objective on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday. Morgan Stanley raised their target price on shares of Personalis from $9.00 to $11.00 and gave the company an “equal weight” rating in a research note on Monday, December 1st. HC Wainwright upped their price target on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $10.71.

Personalis Trading Down 6.0%

Shares of PSNL stock opened at $9.37 on Friday. Personalis has a 1 year low of $2.83 and a 1 year high of $11.50. The firm’s fifty day moving average price is $9.23 and its two-hundred day moving average price is $7.58. The firm has a market capitalization of $832.06 million, a P/E ratio of -10.65 and a beta of 1.96.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. The company had revenue of $14.50 million during the quarter, compared to the consensus estimate of $13.31 million. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. As a group, equities research analysts forecast that Personalis will post -1.4 EPS for the current fiscal year.

Insider Buying and Selling at Personalis

In related news, CEO Christopher M. Hall sold 29,612 shares of Personalis stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $8.99, for a total transaction of $266,211.88. Following the completion of the sale, the chief executive officer owned 148,486 shares of the company’s stock, valued at approximately $1,334,889.14. The trade was a 16.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Aaron Tachibana sold 103,668 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the completion of the transaction, the chief financial officer owned 164,458 shares in the company, valued at approximately $1,772,857.24. This trade represents a 38.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 134,481 shares of company stock worth $1,397,564. Corporate insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Personalis

A number of institutional investors have recently made changes to their positions in PSNL. D.A. Davidson & CO. acquired a new position in shares of Personalis in the fourth quarter valued at approximately $1,158,000. UBS Group AG lifted its holdings in Personalis by 3.7% during the 4th quarter. UBS Group AG now owns 306,568 shares of the company’s stock worth $2,440,000 after purchasing an additional 11,004 shares during the last quarter. Aberdeen Group plc boosted its stake in Personalis by 36.1% in the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after purchasing an additional 861,948 shares during the period. SG Americas Securities LLC acquired a new position in Personalis in the 4th quarter valued at $356,000. Finally, Green Alpha Advisors LLC grew its holdings in Personalis by 141.3% in the 4th quarter. Green Alpha Advisors LLC now owns 68,517 shares of the company’s stock valued at $545,000 after buying an additional 40,126 shares in the last quarter. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.